270
Views
52
CrossRef citations to date
0
Altmetric
Papers

Evaluation of antioxidant and anti-atherogenic properties of Glycyrrhiza glabra root using in vitro models

, PhD, &
Pages 135-149 | Published online: 13 Aug 2009
 

Abstract

The aim of present study was to evaluate antioxidant property of Glycyrrhiza glabra root extracts using in vitro models. The dose-dependent aqueous and ethanolic extracts demonstrated the scavenging activity against nitric oxide (concentration that caused 50% inhibition of nitric oxide radicals [IC50]=72 and 62.1 µg/ml, respectively), superoxide (IC50=64.2 and 38.4 µg/ml, respectively), hydroxyl (IC50=81.9 and 63 µg/ml, respectively), DPPH (IC50=43.6 and 28.3 µg/ml, respectively) and ABTS•+ (IC50=77.3 and 57.2 µg/ml, respectively) radicals. Further, both extracts showed strong reducing power and iron-chelating capacities. In the Fe2+/ascorbate system, both extracts were found to inhibit mitochondrial fraction lipid peroxidation. In copper-catalyzed human serum and low-density lipoprotein oxidation models, both extracts significantly (P<0.05) lengthened the lag phase along with a decline in the oxidation rate, conjugated dienes, lipid hydroperoxides and thiobarbituric acid reactive substance formation. In conclusion, ethanolic extract of G. glabra possess considerable antioxidant activity and protective effect against the human lipoprotein oxidative system.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.